Immune profiling of tumor lysates from patients receiving cancer vaccines suggested a paradigm of two broad phenotypes characterized by the presence or absence of CD8+ effector tumor-infiltrating lymphocytes (TIL) and other mediators of an adaptive immune response [2]. This evidence concerns the gene CD8A and neoplasm.